Donitriptan selectively decreases jugular venous oxygen saturation in the anesthetized pig: Further insights into its mechanism of action relevant to headache relief

Journal of Pharmacology and Experimental Therapeutics

Volumn 305, Issue 2, 2003, Pages 749-754

  Létienne, Robert ^a   Verscheure, Yvan ^a   Perez, Michel ^a   Le Grand, Bruno ^a   Colpaert, Francis C ^a   John, Gareth W ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DONITRIPTAN; MACROGOL; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; SEROTONIN 1B ANTAGONIST; SEROTONIN 1B RECEPTOR;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL OXYGEN SATURATION; ARTERY RESISTANCE; ARTICLE; BLOOD GAS ANALYSIS; BRAIN OXYGEN CONSUMPTION; BRAIN OXYGEN TENSION; CARBON DIOXIDE TENSION; CAROTID ARTERY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG MECHANISM; HEADACHE; JUGULAR VEIN; MALE; NONHUMAN; OXYGEN SATURATION; PRIORITY JOURNAL; SWINE; VENOUS OXYGEN TENSION;

ANESTHESIA; ANIMALS; BLOOD GAS ANALYSIS; CARBON DIOXIDE; CAROTID ARTERIES; ELECTROCARDIOGRAPHY; HEADACHE; HEMODYNAMIC PROCESSES; HEMOGLOBINS; JUGULAR VEINS; MALE; NITRILES; OXADIAZOLES; OXYGEN; PIPERAZINES; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT1D; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SWINE; TRYPTAMINES; VASCULAR RESISTANCE; VASOCONSTRICTION;

EID: 0345352656     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.047225     Document Type: Article

References (28)

1. Clementi E, Brown GC, Foxwell N, and Moncada S (1999) On the mechanism by which vascular endothelial cells regulate their oxygen consumption. Proc Natl Acad Sci USA 96:1559-1562.
2. Dejours P (1963) Physiologie: Les Grandes Fonctions (Kayser C ed) pp 7-246, Êditions Médicales Flammarion, Paris, France.
3. 1D receptor antagonist. Br J Pharmacol 118:85-92.
4. De Vries P, Villalón CM, and Saxena PR (1999a) Pharmacology of triptans. Emerging Drugs 4:107-125.
5. De Vries P, Villalón CM, and Saxena PR (1999b) Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy. Eur J Pharmacol 375:61-74.
6. Dukat M (2001) Donitriptan. Curr Opin Invest Drugs 2:415-418.
7. Farhi LE and Rahn H (1960) Dynamics of changes in carbon dioxide stores. Anesthesiology 21:604-614.
8. 1B/1D receptor agonists in migraine: comparative pharmacology and its therapeutic implications. CNS Drugs 10:271-286.
9. 1B 1D/) receptors. Br J Pharmacol 122:918-922.
10. Heyck H (1969) Pathogenesis of migraine. Res Clin Stud Headache 2:1-28.
11. Hoskin KL, Kaube H, and Goadsby PJ (1996) Sumatriptan can inhibit trigeminal afferents by an exclusively neural mechanism. Brain 119:1419-1428.
12. 1B/1D receptors in models relevant to migraine. J Pharmacol Exp Ther 290:83-95.
13. 1B/1D agonist: key features and acute antimigraine potential. CNS Drug Rev 6:278-289.
14. Johnston BM and Saxena PR (1978) The effect of ergotamine on tissue blood flow and the arteriovenous shunting of radioactive microspheres in the head. Br J Pharmacol 63:541-549.
15. Limmroth V, Katsarava Z, Liedert B, Guehring H, Schmitz K, Diener HC, and Michel MC (2001) An in vivo rat model to study calcitonin gene related peptide release following activation of the trigeminal vascular system. Pain 92:101-106.
16. 1B-immunoreactivity within the human trigemino-cerebrovascular system: implications for the discovery of new antimigraine drugs. Cephalalgia 17:833-842.
17. Moskowitz MA (1992) Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 13:307-311.
18. 1B receptors in human cerebral arteries: pharmacological characterization and localization with immunocytochemistry. Br J Pharmacol 128:1133-1140.
19. 1B receptor activation by sumatriptan and related agonists. Recept Channels 5:367-373.
20. Pauwels PJ and John GW (1999) Present and future of 5-HT receptor agonists as antimigraine drugs. Clin Neuropharmacol 22:123-136.
21. 1 receptor agonists as antimigraine agents. Curr Opin Drug Disc Dev 2:304-310.
22. Riad M, Tong X-K, El Mestikawy, Hamon M, Hamel E, and Descarries L (1998) Endothelial expression of the 5-hydroxytryptamine1B antimigraine drug receptor in rat and human brain microvessels. Neuroscience 86:1031-1035.
23. 1D receptor antagonist. Behav Brain Res 73:157-161.
24. Tfelt-Hansen P, De Vries P, and Saxena PR (2000) Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 60:1259-1287.
25. Tom B, De Vries P, Heiligers JPC, Willems EW, Kapoor K, John GW, and Saxena PR (2002) Effects of donitriptan on carotid hemodynamics and cardiac output distribution in anesthetized pigs. Cephalalgia 22:37-47.
26. 1D receptor antagonists and in situ hybridization. Cephalalgia 22:83-93.
27. Van den Broek RWM, Maassen VanDenBrink A, Mulder PGH, Bogers AJJC, Avezaat CJJ, John GW, and Saxena PR (2002a) Comparison of contractile responses to donitriptan and sumatriptan in the human middle meningeal and coronary arteries. Eur J Pharmacol 443:125-132.
28. 2-adrenoceptors. Br J Pharmacol 126:585-594.